Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
GlobeNewswire Inc.
•
•By Zealand Pharma
Zealand Pharma has partnered with DCAI to access Gefion, Denmark's flagship AI supercomputer, to accelerate drug discovery and development. The agreement will support Zealand Pharma's Metabolic Frontier 2030 strategy, which aims to deliver five launches, over 10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030. Gefion's infrastructure includes over 1,500 NVIDIA GPUs powered by renewable energy, enabling large-scale protein-peptide simulations and advanced AI modeling for drug discovery.